Intellia Stock Declines Around 55% in 3 Months: Here's Why

Key Takeaways NTLA halted MAGNITUDE and MAGNITUDE-2 studies for nex-z after a grade 4 liver event led to a clinical hold.NTLA cancels nex-z milestone guidance and is working with investigators and regulators to plan the next move.NTLA lacks a marketed product, leaving it dependent on partner revenues, which weighs on near-term sentiment.Shares of Intellia Therapeutics (NTLA) have plunged 55.2% over the past three months.The steep decline follows a significant regulatory setback related to nexiguran ziclumer ...